Comparative Pharmacology
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus ROBAXISAL.
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus ROBAXISAL.
CYCLOBENZAPRINE HYDROCHLORIDE vs ROBAXISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.
None Documented
None Documented
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Methocarbamol: 1.0–2.0 hours (prolonged in renal impairment); guaifenesin: approximately 1 hour.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Methocarbamol: renal (primarily as glucuronide and sulfate conjugates, with <2% unchanged); guaifenesin: renal (metabolites, <1% unchanged). No significant biliary/fecal elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant